The Next Big Questions

Transcription

1 Paris

2 The Next Big Questions Why are we different? Why do some develop certain diseases and not others? Why do some respond to therapy and not others? Why do some develop adverse drug reactions? Why do some elderly remain healthy and not others? Scientific projects national & European level 1000 genomes project Cancer genome project Innovative Medicines Initiative Personalized medicine

3 Bottlenecks Samples shortage Fragmentation of research Ethical issues Legal issues

4 The pan-european Scale of BBMRI Leverage effect on national strategies

5 French Network Biobanks CABRI database for microorganisms 1999 OECD best practices for BRC, published in : Several calls to structure the network: Inserm, Inca, ministry of research,anr French norm for biobanks: OECD best practices embeded in ISO 2001: 25 centres accredited 50 centres in 2013

6 2010 Call to set up National infrastructures in Biomedical sciences: Biobanks Clinical research Cohorts High security laboratory (P4) Proteiomics High throughput genomic platform Nanotechnologies for Biomedicine

7 Paris

8 BIOBANQUES A National infrastructure dedicated to medical research based on biological and biomolecular ressources Paris

9 Aims Sustainable access to biological resources of guaranteed quality Elicit and support research consortia at national & international levels Develop innovative technologies Develop public-private partnership Paris

10 Funding Construction Phase millions Euros Opérational Phase: millions Euros

11

12 12

13 Operational phase Common services One stop access to biological resources Interoperability of research data bases Quality management, quality of samples, Biosecurity, Legal & ethical issues in collaboration with ECRIN Methodology & biostatistics Training & dissemination A Platform for validation of biomarkers a privatepublic expert centre. A majorchallenge

14 Technical Platforms High throughput DNA extraction and conservation in neutral gas. Tissue Lyophilisation Platform Cell conservation in dry nitrogen Radiofrequency identification of samples

15 72 biobanks 600 research groups 250 groups: A+ et A

16 Governance Construction phase Scientific Advisory Board Governance Council Stakeholders forum BBMRI ERIC Coordination committee EMbaRC/ MIRRI Biobank Biobank BRC

17 Council Representative of institutional actors Defines strategic orientation of the infrastructure Approves annual program and budget

18 Stakeholders Essential role in the construction and operation of the infrastructure. Different groups: Hospitals(DRM) Private actors researchers Biobanks BBMRI, ESBB, P3G, ISBER Quality managers Patients associations

19 Major features & challenges Integration in a national and European strategy Sustainable funding Evaluation of biobanks Private-public partnership

20

21 Research INFRASTRUCTURE Mutualisation of expertises, means and equipment Paris

22 Cooperation: an added value Bioinformatics Genetics Epidemiology Population-based biobanks Technologies Biomolecular res. Model systems Disease-oriented biobanks Systemic biology Technologies --omics Other disciplines.. Pathology 22

23

24 Evolution of RIs from FP2 to FP7 in FP7 the coverage of scientific domains is balanced.

25 Transnational Access Impact (II) Number of RIs and number of users between FP2 and FP7

26 Transnational Access Impact (I) European researchers consider the TA action to be essential for having access to RIs 90% of the FP6 users have declared that they would not have been able to carry out their work at the RI without EC support (Source: 5050 filled questionnaires) Reasons:

27 Cohorts 200 longitudinal population studies Complex diseases 60% Epidemiology 40% subjects

28 National call Investissements d avenir 2010, cohorts funded for 10 yrs. Total Budget: 100 million

29 Epidemiology CONSTANCE: follow up of subjects, joint program with Helmholtz Institu i-share: risk factors in young subjects, subjects for 10 yrs. Cancer, cardiovascular, neurodegenerative

30 Cancer Canto,: chronic toxicity of breast cancer treatments, 20 00O Patients COBLANce: Blader Cancer, follow up of 2000 patients for 9 yrs. Epidemiologica, economic & pathological data E4N, Breast cancer, follow up of women for 20 yrs (E3N) HOPE-EPI: Cancer in children, follow up of subjects, gene-environment interaction.

31 Chronic diseases CKD-Rein: kidney chronic disease, follow up of patients OFSEP: Sclerosis, follow up of patients PSY-COH: psyciatric, 2000 Young patients for 10 yrs. Schizophrenia, Manic-deression, Asperger syndrome

32 Rare diseases RADICO : 5000 rare diseases, follow up of patients

33 Immunology Cryosystem: disease of the transplant

34 We look forward for joint projects Thank you